Use of oral ketamine in chronic pain management: A review

European Journal of Pain

Volumn 14, Issue 5, 2010, Pages 466-472

  Blonk, Maren I ^a   Koder, Brigitte G ^a   Bemt, Patricia M L A van den ^a,b   Huygen, Frank J P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Chronic pain; Ketamine; Neuropathic pain; Oral administration; Review

Indexed keywords

ANALGESIC AGENT; DEXTROMETHORPHAN; DIAZEPAM; DIPYRONE; DRUG METABOLITE; GLYCERYL TRINITRATE; HALOPERIDOL; HYPNOTIC AGENT; KETAMINE; LIVER ENZYME; MORPHINE; NORKETAMINE; PETHIDINE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALLODYNIA; ANALGESIC ACTIVITY; ANOREXIA; ANXIETY; BEDTIME DOSAGE; BLOOD PRESSURE; BLURRED VISION; BOLUS INJECTION; CANCER PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CHRONIC PAIN; CLINICAL TRIAL; COCHRANE LIBRARY; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONFUSION; DEPRESSION; DIABETIC NEUROPATHY; DISSOCIATIVE DISORDER; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHORIA; EMBASE; EPILEPTIC FOCUS; EUPHORIA; FACE PAIN; FATIGUE; GASTROINTESTINAL SYMPTOM; GLOSSOPHARYNGEAL NEURALGIA; HALLUCINATION; HEARING IMPAIRMENT; HEART RATE; HUMAN; HYPERALGESIA; ILLUSION; INJECTION SITE INFLAMMATION; INSOMNIA; INTERMITTENT CLAUDICATION; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; MEMORY DISORDER; MENTAL DISEASE; MOUTH PAIN; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROTOXICITY; NIGHTMARE; OPTIMAL DRUG DOSE; PAIN; PARANOIA; PHANTOM PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; RACEMIC MIXTURE; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH ULCER; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN; VISUAL HALLUCINATION; VIVID DREAM; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ANALGESICS; CHRONIC DISEASE; HUMANS; KETAMINE; PAIN;

EID: 77951878720     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2009.09.005     Document Type: Review

References (48)

1. Arendt-Nielsen L., Nielsen J., Petersen-Felix S., Schnider T.W., and Zbinden A.M. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Brit J Anaesth 77 (1996) 625-631
2. Ben-Ari A., Lewis M.C., and Davidson E. Chronic administration of ketamine for analgesia. J Pain Palliat Care Pharmacother 21 (2007) 7-14
3. Benitez-Rosario M.A., Feria M., Salinas-Martin A., Martinez-Castillo L.P., and Martin-Ortega J.J. A retrospective comparison of the dose ratio between subcutaneous and oral ketamine. J Pain Symptom Manage 25 (2003) 400-402
4. Bennett G.J. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 19 Suppl. 1 (2000) S2-6
5. Broadley K.E., Kurowska A., and Tookman A. Ketamine injection used orally. Palliative Med 10 (1996) 247-250
6. Bushnell T.G., and Craig J. Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine?. Pain 60 (1995) 115
7. Clements J.A., Nimmo W.S., and Grant I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71 (1982) 539-542
8. Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 9 (2008) 253-257
9. Ebert B., Mikkelsen S., Thorkildsen C., and Borgbjerg F.M. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333 (1997) 99-104
10. Eichenberger U., Neff F., Sveticic G., Bjorgo S., Petersen-Felix S., Arendt-Nielsen L., et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg 106 (2008) 1265-1273
11. Eide P.K. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 4 (2000) 5-15
12. Eide P.K., and Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade. Neurosurgery 41 (1997) 505-508
13. Eide K., Stubhaug A., Oye I., and Breivik H. Continuous subcutaneous administration of the N-methyl-d-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 61 (1995) 221-228
14. Enarson M.C., Hays H., and Woodroffe M.A. Clinical experience with oral ketamine. J Pain Symptom Manage 17 (1999) 384-386
15. Fisher K., and Hagen N.A. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. J Pain Symptom Manage 18 (1999) 61-66
16. Fisher K., Coderre T.J., and Hagen N.A. Targeting the N-methyl-d-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 20 (2000) 358-373
17. Fitzgibbon E.J., Hall P., Schroder C., Seely J., and Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 23 (2002) 165-170
18. Friedman R., Li V., Kueppers F., and Atkinson G. Oral ketamine in hepatocellular carcinoma. Pain Med 1 (2000) 181-182
19. Furuhashi-Yonaha A., Iida H., Asano T., Takeda T., and Dohi S. Short- and long-term efficacy of oral ketamine in eight chronic-pain patients. Can J Anaesth 49 (2002) 886-887
20. Grant I.S., Nimmo W.S., and Clements J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Brit J Anaesth 53 (1981) 805-810
21. Haines D.R., and Gaines S.P. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 83 (1999) 283-287
22. Hocking G., and Cousins M.J. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 97 (2003) 1730-1739
23. Hoffmann V., Coppejans H., Vercauteren M., and Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain 10 (1994) 240-242
24. Holtman Jr. J.R., Crooks P.A., Johnson-Hardy J.K., Hojomat M., Kleven M., and Wala E.P. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 90 (2008) 676-685
25. Jensen L.L., Handberg G., Helbo-Hansen H.S., Skaarup I., Lohse T., Munk T., et al. No morphine sparing effect of ketamine added to morphine for patient-controlled intravenous analgesia after uterine artery embolization. Acta Anaesthesiol Scand 52 (2008) 479-486
26. Kannan T.R., Saxena A., Bhatnagar S., and Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 23 (2002) 60-65
27. Kapur N., and Friedman R. Oral ketamine: a promising treatment for restless legs syndrome. Anesth Analg 94 (2002) 1558-1559
28. Ketanest-S5, solution for injection 5mg/ml Summary of product characteristics. RVG 22550, 19 Jan 1999. Available from: www.CBG-MEB.nl.
29. Kiefer R.T., Rohr P., Ploppa A., Dieterich H.J., Grothusen J., Koffler S., et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med 9 (2008) 1173-1201
30. Klepstad P., and Borchgrevink P.C. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 41 (1997) 422-426
31. Kohrs R., and Durieux M.E. Ketamine: teaching an old drug new tricks. Anesth Analg 87 (1998) 1186-1193
32. Kronenberg R.H. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother 16 (2002) 27-35
33. Lauretti G.R., Lima I.C., Reis M.P., Prado W.A., and Pereira N.L. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 90 (1999) 1528-1533
34. Mathisen L.C., Skjelbred P., Skoglund L.A., and Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 61 (1995) 215-220
35. Mercadante S., Arcuri E., Tirelli W., and Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 20 (2000) 246-252
36. Morgan C.J., Muetzelfeldt L., and Curran H.V. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104 (2009) 77-87
37. Muetzelfeldt L., Kamboj S.K., Rees H., Taylor J., Morgan C.J., and Curran H.V. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 95 (2008) 219-229
38. Nikolajsen L., Hansen P.O., and Jensen T.S. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand 41 (1997) 427-429
39. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 10 (2007) 493-500
40. Persson J. The ketamine enigma. Acta Anaesthesiol Scand 52 (2008) 453-455
41. Rabben T., and Oye I. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. Eur J Pain 5 (2001) 233-240
42. Rabben T., Skjelbred P., and Oye I. Prolonged analgesic effect of ketamine, an N-methyl-d-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 289 (1999) 1060-1066
43. Sakai T., Tomiyasu S., Ono T., Yamada H., and Sumikawa K. Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. Clin J Pain 20 (2004) 375-376
44. Vick P.G., and Lamer T.J. Treatment of central post-stroke pain with oral ketamine. Pain 92 (2001) 311-313
45. Villanueva-Perez V.L., Cerda-Olmedo G., Samper J.M., Minguez A., Monsalve V., Bayona M.J., et al. Oral ketamine for the treatment of type I complex regional pain syndrome. Pain Pract 7 (2007) 39-43
46. Visser E., and Schug S.A. The role of ketamine in pain management. Biomed Pharmacother 60 (2006) 341-348
47. Vranken J.H., Troost D., Wegener J.T., Kruis M.R., and Van der Vegt M.H. Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. Pain 117 (2005) 231-235
48. White P.F., Way W.L., and Trevor A.J. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 56 (1982) 119-136